ClinicalTrials.gg
CompletedNCT03537508Updated Oct 15, 2024Results posted

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

A Phase 3 interventional study of MenACYW conjugate vaccine and MenACYW-135 conjugate vaccine in Healthy Volunteers (Meningococcal Infection), sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 70 sites in 2 countries. Open to participants aged 42 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,627
Allocation
Randomized
Ages
42 Days to 89 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies in Meningococcal Infections by Sanofi — 2 open to participants now, 2 under way, 1 of them phase 3. Meningococcal Infections · Sanofi.

Enrollment
4th of 51
2,627 · median 378
Started
2018
with 6 others
Phase 3
25 of 57
1 open now
Registered
46th of 57
by date

Among the 57 studies in Meningococcal Infections by Sanofi, this one is the 4th largest by enrollment of the 51 interventional ones that give a count, is one of 7 that started in 2018, is one of 25 in phase 3, and was the 46th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

2 of the 57 studies in Meningococcal Infections by Sanofi are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 42 Days to 89 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Meningococcal Infections by Sanofi, or all of them as a file.
02

Study summary

The purpose of this study was to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when both are administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in the US.

Read the detailed description

The duration of each subject's participation in the trial was approximately 16 to 19 months (Subgroup 1a) and 19 to 22 months (Subgroup 1b and Group 2), which included a safety follow up contact at 6 months after the last vaccinations.

03

Conditions studied

  • Healthy Volunteers (Meningococcal Infection)

Keywords

  • Meningococcal meningitis
  • MenACYW conjugate vaccine
  • Quadrivalent meningococcal vaccine
04

Who can participate

Ages eligible
42 Days to 89 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 42 to ≤ 89 days on the day of the first study visit.
  • Healthy infants as determined by medical history, physical examination, and judgment of the investigator
  • form has been signed and dated by the parent(s) or guardian, and an independent witness, if required by local regulations
  • Participant and parent/guardian were able to attend all scheduled visits and to comply with all trial procedures.
  • Infants who received the first dose of vaccine at least 28 days before the first study visit

Exclusion criteria

Exclusion Criteria:

  • Participation at the time of study enrollment or in the 4 weeks preceding the first trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
  • Receipt of any vaccine in the 4 weeks preceding the first trial vaccination or planned receipt of any vaccine in the 4 weeks before and/or following any trial vaccination except for influenza vaccination, which could have been received at a gap of at least 2 weeks before or 2 weeks after any study vaccination. This exception included monovalent pandemic influenza vaccines and multivalent influenza vaccines
  • Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (i.e., mono- or polyvalent, PS, or conjugate meningococcal vaccine containing serogroups A, C, Y, or W; or meningococcal B serogroup-containing vaccine).
  • Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis A, measles, mumps, rubella, varicella; and of Haemophilus influenzae type b, Streptococcus pneumoniae, and /or rotavirus infection or disease
  • Receipt of more than 1 previous dose of vaccine
  • Receipt of immune globulins, blood, or blood-derived products since birth
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks) since birth
  • Family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated
  • Individuals with blood dyscrasias, leukemia, lymphoma of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems
  • Individuals with active tuberculosis
  • History of any Neisseria meningitidis infection, confirmed either clinically, serologically, or microbiologically
  • History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, hepatitis A, measles, mumps, rubella, varicella; and of Haemophilus influenzae type b, Streptococcus pneumoniae, and /or rotavirus infection or disease
  • At high risk for meningococcal infection during the trial (specifically, but not limited to, subjects with persistent complement deficiency, with anatomic or functional asplenia, or subjects travelling to countries with high endemic or epidemic disease)
  • History of intussusception
  • History of any neurologic disorders, including any seizures and progressive neurologic disorders
  • History of Guillain-Barré syndrome
  • Known systemic to any of the vaccine components or to latex, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances, including neomycin, gelatin, and yeast
  • Verbal report of thrombocytopenia contraindicating intramuscular vaccination in the investigator's opinion
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination in the investigator's opinion
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw
  • Chronic illness (including, but not limited to, cardiac disorders, congenital heart disease, chronic lung disease, renal disorders, auto-immune disorders, diabetes, psychomotor diseases, and known congenital or genetic diseases) that in the opinion of the investigator, was at a stage where it might have interfered with trial conduct or completion
  • Any condition which, in the opinion of the investigator, might have interfered with the evaluation of the study objectives
  • Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]). A prospective participant was not included in the study until the condition has been resolved or the febrile event has been subsided
  • Identified as a natural or adopted child of the investigator or employee with direct involvement in the proposed study
  • The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,627 participants (actual)

Study arms

  • Experimental
    Group 1a

    MenACYW conjugate vaccine and routine vaccines at 2, 4, 6, and 12 to 15 months of age

    Biological: MenACYW conjugate vaccine · Biological: DTaP-IPV//Hib vaccine · Biological: Pneumococcal 13-valent conjugate vaccine · Biological: Pentavalent rotavirus vaccine · Biological: Hepatitis B vaccine · Biological: Measles, mumps, rubella (MMR) vaccine · Biological: Varicella vaccine

  • Experimental
    Group 1b

    MenACYW conjugate vaccine at 2, 4, 6, and 15 to 18 months of age and routine vaccines at 2, 4, 6, 12 to 15 months of age, and 15 to 18 months of age

    Biological: MenACYW conjugate vaccine · Biological: DTaP-IPV//Hib vaccine · Biological: Pneumococcal 13-valent conjugate vaccine · Biological: Pentavalent rotavirus vaccine · Biological: Hepatitis B vaccine · Biological: Measles, mumps, rubella (MMR) vaccine · Biological: Varicella vaccine · Biological: Hepatitis A vaccine

  • Active comparator
    Group 2a

    MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age

    Biological: MenACYW-135 conjugate vaccine · Biological: DTaP-IPV//Hib vaccine · Biological: Pneumococcal 13-valent conjugate vaccine · Biological: Pentavalent rotavirus vaccine · Biological: Hepatitis B vaccine · Biological: Measles, mumps, rubella (MMR) vaccine · Biological: Varicella vaccine

  • Active comparator
    Group 2b

    MENVEO® at 2, 4, 6, and 12 months of age and routine vaccines at 2, 4, 6, 12, and 15 to 18 months of age

    Biological: MenACYW-135 conjugate vaccine · Biological: DTaP-IPV//Hib vaccine · Biological: Pneumococcal 13-valent conjugate vaccine · Biological: Pentavalent rotavirus vaccine · Biological: Hepatitis B vaccine · Biological: Measles, mumps, rubella (MMR) vaccine · Biological: Varicella vaccine · Biological: Hepatitis A vaccine

Interventions

  • BiologicalMenACYW conjugate vaccine

    Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular

  • BiologicalMenACYW-135 conjugate vaccine

    Meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, 0.5 mL, intramuscular

    Also known as: MENVEO®

  • BiologicalDTaP-IPV//Hib vaccine

    Drug page: Pentacel

    DTaP-IPV//Hib vaccine at 2, 4, 6 and 12 to 15 (Group 1a)/15-18 (Group 1b and Group 2) months of age Intramuscular

    Also known as: Pentacel®

  • Pneumococcal vaccine at 2, 4, 6, and 12 months of age, Intramuscular

    Also known as: PREVNAR 13®

  • Rotavirus vaccine at 2, 4, and 6 months of age, oral solution

    Also known as: RotaTeq®

  • BiologicalHepatitis B vaccine

    Hepatitis B vaccine at 2 and 6 months of age, Intramuscular

    Also known as: ENGERIX-B®

  • MMR vaccine at 12 months of age, Subcutaneous

    Also known as: M-M-R® II

  • Varicella vaccine at 12 months of age

    Also known as: VARIVAX®

  • BiologicalHepatitis A vaccine

    Hepatitis A vaccine at 15 to 18 months of age

    Also known as: HAVRIX®

06

What researchers measure

Primary outcomes

  1. Groups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. Vaccine seroresponse was defined as a post 4th dose (Day 30 after 12-month) hSBA titer \>=1:16 for participants with pre 1st dose (Day 0 before 2-month) hSBA titer less than (\<) 1:8, or at least a 4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8. Percentages are rounded off to the tenth decimal place.

    Time frame: Day 30 post 12-month vaccination (Month 13)

  2. Groups 1 and 2: Percentage of Participants Who Achieved Antibody Titers >=1:8 by hSBA at Day 30 Post 6-Month Vaccination

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. Percentages are rounded off to the tenth decimal place.

    Time frame: Day 30 post 6-month vaccination (Month 7)

Secondary outcomes

  1. Groups 1 and 2: Percentage of Participants Who Achieved Anti-Hepatitis B Antibody Concentrations >=10 Milli-International Units Per Milliliter (mIU/mL) at Day 30 Post 6-Month Vaccination

    Anti-Hepatitis B surface antibodies (HBsAg) were measured by the commercially available VITROS ECi/ECiQ immunodiagnostic system using chemiluminescence detection technology. The percentage of participants with an anti-HBsAg antibody titer \>=10 mIU/mL was assessed. Percentages are rounded off to the tenth decimal place.

    Time frame: Day 30 post 6-month vaccination (Month 7)

  2. Groups 1 and 2: Percentage of Participants Who Achieved Anti-Polyribosyl-Ribitol (PRP) Antibody Concentrations >=0.15 and >=1.0 Microgram (mcg)/mL at Day 30 Post 6-Month Vaccination

    Anti-PRP concentrations were measured using a farr-type radioimmunoassay (RIA). The percentage of participants with an PRP antibody titer \>=0.15 mcg/mL and \>=1.0 mcg/mL were assessed. Percentages are rounded off to the tenth decimal place.

    Time frame: Day 30 post 6-month vaccination (Month 7)

  3. Groups 1 and 2: Percentage of Participants Who Achieved Anti-Poliovirus Antibody Titers >=1:8 at Day 30 Post 6-Month Vaccination

    Anti-poliovirus types 1, 2, and 3 were measured by neutralization assay. The percentage of participants with anti-polio antibody titers \>=1:8 were assessed.

    Time frame: Day 30 post 6-month vaccination (Month 7)

  4. Groups 1 and 2: Percentage of Participants Who Achieved Anti-Rotavirus Immunoglobulin A (IgA) Antibody Concentrations >=3-Fold Rise at Day 30 Post 6-Month Vaccination

    Anti-rotavirus IgA antibodies in human serum were measured by enzyme-linked immunosorbent assay (ELISA). The percentage of participants who achieved anti-rotavirus IgA Ab concentrations \>=3-fold rise were assessed. Percentages are rounded off to the tenth decimal place.

    Time frame: Day 30 post 6-month vaccination (Month 7)

  5. Groups 1 and 2: Geometric Mean Concentrations (GMCs) of Anti-Rotavirus IgA Antibodies at Day 30 Post 6-Month Vaccination

    GMCs of anti-rotavirus serum IgA antibodies were assessed using ELISA.

    Time frame: Day 30 post 6-month vaccination (Month 7)

  6. Groups 1 and 2: GMCs of Anti-Pertussis Antibodies at Day 30 Post 6-Month Vaccination

    GMCs of anti-pertussis antibodies (pertussis toxoid \[PT\], filamentous hemagglutinin adhesin \[FHA\], pertactin \[PRN\] and fimbriae types 2 and 3 \[FIM\]) were measured by electrochemiluminescent (ECL) assay.

    Time frame: Day 30 post 6-month vaccination (Month 7)

  7. Groups 1 and 2: GMCs of Anti-Pneumococcal Antibodies at Day 30 Post 6-Month Vaccination

    GMCs of anti-pneumococcal antibodies was assessed by pneumococcal capsular polysaccharide (PnPS) IgG ECL assay which is used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) antibodies in human serum.

    Time frame: Day 30 post 6-month vaccination (Month 7)

  8. Groups 1a and 2a: Percentage of Participants Who Achieved Vaccine Response for Measles, Mumps and Rubella (MMR) Antibodies at Day 30 Post 12-Month Vaccination

    Vaccine response against anti-measles and anti-rubella antibodies were measured by bulk IgG enzyme immunoassay and anti-mumps antibodies were assessed by ELISA. Percentage of participants with anti-measles, anti-mumps, anti-rubella antibody concentration that met the respective mentioned criterion are reported: measles: \>=255 mIU/mL; mumps: \>=10 antibody units per milliliter and rubella: \>=10 IU/mL. Percentages are rounded off to the tenth decimal place.

    Time frame: Day 30 post 12-month vaccination (Month 13)

  9. Groups 1a and 2a: Percentage of Participants Who Achieved Vaccine Response for Varicella Antibodies at Day 30 Post 12-Month Vaccination

    Vaccine response against anti-varicella antibodies were measured by glycoprotein (gp) ELISA. Percentage of participants with anti-varicella antibody concentration \>=5 antibody (Ab) gpELISA units/mL are reported. Percentages are rounded off to the tenth decimal place.

    Time frame: Day 30 post 12-month vaccination (Month 13)

  10. Groups 1a and 2a: GMCs of Anti-Pneumococcal Antibodies at Day 30 Post 12-Month Vaccination

    GMCs of anti-pneumococcal antibodies was assessed by PnPS IgG ECL assay which is used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) antibodies in human serum.

    Time frame: Day 30 post 12-month vaccination (Month 13)

  11. Groups 1b and 2b: Percentage of Participants Who Achieved Anti-PRP Antibody Concentrations >=1.0 mcg/mL at Day 30 Post 15-Month Vaccination

    Anti-PRP concentrations were measured using a farr-type RIA. The percentage of participants with an PRP antibody titers \>=1.0 mcg/mL were assessed. Percentages are rounded off to the tenth decimal place.

    Time frame: Day 30 post 15-month vaccination (Month 16)

  12. Groups 1b and 2b: Percentage of Participants Who Achieved Anti-Poliovirus Antibody Titers >=1:8 at Day 30 Post 15-Month Vaccination

    Anti-poliovirus types 1, 2, and 3 were measured by neutralization assay. The percentage of participants with anti-polio antibody titers \>=1:8 are assessed.

    Time frame: Day 30 post 15-month vaccination (Month 16)

  13. Groups 1b and 2b: Percentage of Participants Who Achieved Vaccine Response for Anti-Pertussis Antibodies at Day 30 Post 15-Month Vaccination

    Vaccine response was defined as: if the pre-booster (4th) vaccination concentration was \<lower limit of quantification (LLOQ), then the post-booster (4th) vaccination concentration should be \>=4 times LLOQ. The LLOQ was equal to 2.00 EU/mL. Percentages are rounded off to the tenth decimal place.

    Time frame: Day 30 post 15-month vaccination (Month 16)

  14. Groups 1a and 2a: Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA at Day 30 Post 6-Month Vaccination and Day 0 Before 12-Month Vaccination

    GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. PPAS2 included participants of FAS2 (subset of all randomized participants who received \>=1 dose of the study vaccine in infancy \[at Visit 1 to 3, \< 12 months of age\] and had a valid pre-vaccination serology result at Visit 5 before the 12-month vaccinations for Subgroups 1a and 2a or at Visit 6 before the 15-month vaccinations for Subgroups 1b and 2b) with no relevant protocol deviations during infancy and for whom a pre-dose serology sample at Visit 5 for Subgroups 1a and 2a before the 12-month vaccinations or Visit 6 for Subgroups 1b and 2b before the 15-month vaccinations was not withdrawn.

    Time frame: Day 30 post 6-month vaccination (Month 7) and Day 0 before 12-month vaccination (Month 12)

  15. Groups 1a and 2a: Percentage of Participants Who Achieved Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W at Day 30 Post 6-Month Vaccination and Day 0 Before 12-Month Vaccination

    Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. PPAS2 included participants of FAS2 with no relevant protocol deviations during infancy and for whom a pre-dose serology sample at Visit 5 for Subgroups 1a and 2a before the 12-month vaccinations or Visit 6 for Subgroups 1b and 2b before the 15-month vaccinations was not withdrawn. Percentages are rounded off to the tenth decimal place.

    Time frame: Day 30 post 6-month vaccination (Month 7) and Day 0 before 12-month vaccination (Month 12)

07

Results

Posted Oct 15, 2024

Participant flow

The study was conducted at 69 investigational sites in Puerto Rico and the United States. Healthy infants aged \>=42 to \<=89 days were randomized in 2:1 ratio to either Group 1: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine (MenACYW conjugate vaccine) and routine pediatric vaccines or Group 2: Meningococcal (groups A, C, Y, and W-135) oligosaccharide diphtheria cross reacting material (CRM) 197 conjugate vaccine (MENVEO®) and routine pediatric vaccines.

Participant flow — Overall Study
MilestoneGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO
Started1746881
Safety analysis set (safas)1727867
Vaccinated at 2 months1727869
Vaccinated at 4 months1619828
Vaccinated at 6 months1543793
Vaccinated at 12 months1411708
Vaccinated at 15 months445644
Completed1330623
Not completed416258
Withdrew: Adverse event21
Withdrew: Protocol violation6548
Withdrew: Lost to follow-up8660
Withdrew: Withdrawal by parent/guardian263149

Outcome measures

PrimaryGroups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. Vaccine seroresponse was defined as a post 4th dose (Day 30 after 12-month) hSBA titer \>=1:16 for participants with pre 1st dose (Day 0 before 2-month) hSBA titer less than (\<) 1:8, or at least a 4-fold increase in hSBA titer from pre-vaccination to post-vaccination for participants with pre-vaccination hSBA titer \>=1:8. Percentages are rounded off to the tenth decimal place.

Time frame:
Day 30 post 12-month vaccination (Month 13)
Reported as:
Number · percentage of participants
Groups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination
percentage of participantsGroup 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination)Group 2a: MENVEO (Post 12-month Vaccination)
Serogroup A79.4 (75.6 to 82.9)77.6 (71.5 to 82.9)
Serogroup C97.0 (95.1 to 98.3)88.2 (83.4 to 92.0)
Serogroup Y96.4 (94.4 to 97.8)92.3 (88.1 to 95.4)
Serogroup W97.6 (95.9 to 98.7)96.4 (93.3 to 98.3)
Statistical analysis
  • Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) vs Group 2a: MENVEO (Post 12-month Vaccination) · Difference in percentage of participants: 1.86 · 95% CI -4.38 to 8.64
  • Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) vs Group 2a: MENVEO (Post 12-month Vaccination) · Difference in percentage of participants: 8.75 · 95% CI 4.80 to 13.60
  • Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) vs Group 2a: MENVEO (Post 12-month Vaccination) · Difference in percentage of participants: 4.09 · 95% CI 0.68 to 8.44
  • Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination) vs Group 2a: MENVEO (Post 12-month Vaccination) · Difference in percentage of participants: 1.19 · 95% CI -1.18 to 4.45
PrimaryGroups 1 and 2: Percentage of Participants Who Achieved Antibody Titers >=1:8 by hSBA at Day 30 Post 6-Month Vaccination

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. Percentages are rounded off to the tenth decimal place.

Time frame:
Day 30 post 6-month vaccination (Month 7)
Reported as:
Number · percentage of participants
Groups 1 and 2: Percentage of Participants Who Achieved Antibody Titers >=1:8 by hSBA at Day 30 Post 6-Month Vaccination
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO
Serogroup A77.9 (75.0 to 80.7)67.7 (63.0 to 72.2)
Serogroup C99.0 (98.1 to 99.6)91.2 (88.1 to 93.7)
Serogroup Y98.3 (97.1 to 99.0)91.7 (88.7 to 94.2)
Serogroup W98.6 (97.6 to 99.3)92.9 (90.1 to 95.1)
Statistical analysis
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO · Difference in percentage of participants: 10.21 · 95% CI 4.98 to 15.59
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO · Difference in percentage of participants: 7.83 · 95% CI 5.31 to 10.96
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO · Difference in percentage of participants: 6.53 · 95% CI 4.01 to 9.62
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO · Difference in percentage of participants: 5.72 · 95% CI 3.44 to 8.57
SecondaryGroups 1 and 2: Percentage of Participants Who Achieved Anti-Hepatitis B Antibody Concentrations >=10 Milli-International Units Per Milliliter (mIU/mL) at Day 30 Post 6-Month Vaccination

Anti-Hepatitis B surface antibodies (HBsAg) were measured by the commercially available VITROS ECi/ECiQ immunodiagnostic system using chemiluminescence detection technology. The percentage of participants with an anti-HBsAg antibody titer \>=10 mIU/mL was assessed. Percentages are rounded off to the tenth decimal place.

Time frame:
Day 30 post 6-month vaccination (Month 7)
Reported as:
Number · percentage of participants
Groups 1 and 2: Percentage of Participants Who Achieved Anti-Hepatitis B Antibody Concentrations >=10 Milli-International Units Per Milliliter (mIU/mL) at Day 30 Post 6-Month Vaccination
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO
Groups 1 and 2: Percentage of Participants Who Achieved Anti-Hepatitis B Antibody Concentrations >=10 Milli-International Units Per Milliliter (mIU/mL) at Day 30 Post 6-Month Vaccination98.6 ± 97.498.0 ± 95.9
SecondaryGroups 1 and 2: Percentage of Participants Who Achieved Anti-Polyribosyl-Ribitol (PRP) Antibody Concentrations >=0.15 and >=1.0 Microgram (mcg)/mL at Day 30 Post 6-Month Vaccination

Anti-PRP concentrations were measured using a farr-type radioimmunoassay (RIA). The percentage of participants with an PRP antibody titer \>=0.15 mcg/mL and \>=1.0 mcg/mL were assessed. Percentages are rounded off to the tenth decimal place.

Time frame:
Day 30 post 6-month vaccination (Month 7)
Reported as:
Number · percentage of participants
Groups 1 and 2: Percentage of Participants Who Achieved Anti-Polyribosyl-Ribitol (PRP) Antibody Concentrations >=0.15 and >=1.0 Microgram (mcg)/mL at Day 30 Post 6-Month Vaccination
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO
>=0.15 mcg/mL99.0 ± 98.196.4 ± 94.2
>=1.0 mcg/mL91.3 ± 89.285.7 ± 82.0
SecondaryGroups 1 and 2: Percentage of Participants Who Achieved Anti-Poliovirus Antibody Titers >=1:8 at Day 30 Post 6-Month Vaccination

Anti-poliovirus types 1, 2, and 3 were measured by neutralization assay. The percentage of participants with anti-polio antibody titers \>=1:8 were assessed.

Time frame:
Day 30 post 6-month vaccination (Month 7)
Reported as:
Number · percentage of participants
Groups 1 and 2: Percentage of Participants Who Achieved Anti-Poliovirus Antibody Titers >=1:8 at Day 30 Post 6-Month Vaccination
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO
Anti-polio 1100 (99.6 to 100)100 (99.1 to 100)
Anti-polio 2100 (99.6 to 100)100 (99.1 to 100)
Anti-polio 3100 (99.6 to 100)100 (99.1 to 100)
SecondaryGroups 1 and 2: Percentage of Participants Who Achieved Anti-Rotavirus Immunoglobulin A (IgA) Antibody Concentrations >=3-Fold Rise at Day 30 Post 6-Month Vaccination

Anti-rotavirus IgA antibodies in human serum were measured by enzyme-linked immunosorbent assay (ELISA). The percentage of participants who achieved anti-rotavirus IgA Ab concentrations \>=3-fold rise were assessed. Percentages are rounded off to the tenth decimal place.

Time frame:
Day 30 post 6-month vaccination (Month 7)
Reported as:
Number · percentage of participants
Groups 1 and 2: Percentage of Participants Who Achieved Anti-Rotavirus Immunoglobulin A (IgA) Antibody Concentrations >=3-Fold Rise at Day 30 Post 6-Month Vaccination
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO
Groups 1 and 2: Percentage of Participants Who Achieved Anti-Rotavirus Immunoglobulin A (IgA) Antibody Concentrations >=3-Fold Rise at Day 30 Post 6-Month Vaccination91.0 ± 88.592.8 ± 89.4
SecondaryGroups 1 and 2: Geometric Mean Concentrations (GMCs) of Anti-Rotavirus IgA Antibodies at Day 30 Post 6-Month Vaccination

GMCs of anti-rotavirus serum IgA antibodies were assessed using ELISA.

Time frame:
Day 30 post 6-month vaccination (Month 7)
Reported as:
Geometric mean · Units/mL
Groups 1 and 2: Geometric Mean Concentrations (GMCs) of Anti-Rotavirus IgA Antibodies at Day 30 Post 6-Month Vaccination
Units/mLGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO
Groups 1 and 2: Geometric Mean Concentrations (GMCs) of Anti-Rotavirus IgA Antibodies at Day 30 Post 6-Month Vaccination272 ± 244308 ± 264
SecondaryGroups 1 and 2: GMCs of Anti-Pertussis Antibodies at Day 30 Post 6-Month Vaccination

GMCs of anti-pertussis antibodies (pertussis toxoid \[PT\], filamentous hemagglutinin adhesin \[FHA\], pertactin \[PRN\] and fimbriae types 2 and 3 \[FIM\]) were measured by electrochemiluminescent (ECL) assay.

Time frame:
Day 30 post 6-month vaccination (Month 7)
Reported as:
Geometric mean · ELISA units/mL
Groups 1 and 2: GMCs of Anti-Pertussis Antibodies at Day 30 Post 6-Month Vaccination
ELISA units/mLGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO
Anti-PT75.8 ± 72.278.6 ± 72.8
Anti-FHA95.7 ± 90.998.6 ± 91.7
Anti-PRN39.4 ± 36.842.1 ± 37.9
Anti-FIM309 ± 291311 ± 284
SecondaryGroups 1 and 2: GMCs of Anti-Pneumococcal Antibodies at Day 30 Post 6-Month Vaccination

GMCs of anti-pneumococcal antibodies was assessed by pneumococcal capsular polysaccharide (PnPS) IgG ECL assay which is used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) antibodies in human serum.

Time frame:
Day 30 post 6-month vaccination (Month 7)
Reported as:
Geometric mean · mcg/mL
Groups 1 and 2: GMCs of Anti-Pneumococcal Antibodies at Day 30 Post 6-Month Vaccination
mcg/mLGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO
Serotype 12.26 (2.13 to 2.40)1.93 (1.77 to 2.12)
Serotype 30.607 (0.577 to 0.638)0.544 (0.505 to 0.585)
Serotype 41.46 (1.40 to 1.53)1.33 (1.24 to 1.42)
Serotype 51.54 (1.46 to 1.63)1.26 (1.15 to 1.37)
Serotype 6A4.01 (3.82 to 4.22)3.34 (3.09 to 3.62)
Serotype 6B2.47 (2.29 to 2.67)1.97 (1.75 to 2.21)
Serotype 7F3.48 (3.32 to 3.64)3.40 (3.18 to 3.63)
Serotype 9V1.88 (1.78 to 1.99)1.61 (1.48 to 1.74)
Serotype 146.95 (6.53 to 7.41)7.17 (6.58 to 7.81)
Serotype 18C1.95 (1.86 to 2.04)1.82 (1.69 to 1.96)
Serotype 19A2.21 (2.10 to 2.32)2.00 (1.86 to 2.14)
Serotype 19F3.36 (3.21 to 3.52)2.98 (2.77 to 3.21)
Serotype 23F1.59 (1.49 to 1.69)1.30 (1.18 to 1.44)
SecondaryGroups 1a and 2a: Percentage of Participants Who Achieved Vaccine Response for Measles, Mumps and Rubella (MMR) Antibodies at Day 30 Post 12-Month Vaccination

Vaccine response against anti-measles and anti-rubella antibodies were measured by bulk IgG enzyme immunoassay and anti-mumps antibodies were assessed by ELISA. Percentage of participants with anti-measles, anti-mumps, anti-rubella antibody concentration that met the respective mentioned criterion are reported: measles: \>=255 mIU/mL; mumps: \>=10 antibody units per milliliter and rubella: \>=10 IU/mL. Percentages are rounded off to the tenth decimal place.

Time frame:
Day 30 post 12-month vaccination (Month 13)
Reported as:
Number · percentage of participants
Groups 1a and 2a: Percentage of Participants Who Achieved Vaccine Response for Measles, Mumps and Rubella (MMR) Antibodies at Day 30 Post 12-Month Vaccination
percentage of participantsGroup 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination)Group 2a: MENVEO (Post 12-month Vaccination)
Anti-measles97.6 (96.1 to 98.6)97.3 (94.8 to 98.8)
Anti-mumps95.5 (93.6 to 96.9)97.7 (95.3 to 99.1)
Anti-rubella97.9 (96.5 to 98.8)98.0 (95.7 to 99.3)
SecondaryGroups 1a and 2a: Percentage of Participants Who Achieved Vaccine Response for Varicella Antibodies at Day 30 Post 12-Month Vaccination

Vaccine response against anti-varicella antibodies were measured by glycoprotein (gp) ELISA. Percentage of participants with anti-varicella antibody concentration \>=5 antibody (Ab) gpELISA units/mL are reported. Percentages are rounded off to the tenth decimal place.

Time frame:
Day 30 post 12-month vaccination (Month 13)
Reported as:
Number · percentage of participants
Groups 1a and 2a: Percentage of Participants Who Achieved Vaccine Response for Varicella Antibodies at Day 30 Post 12-Month Vaccination
percentage of participantsGroup 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination)Group 2a: MENVEO (Post 12-month Vaccination)
Groups 1a and 2a: Percentage of Participants Who Achieved Vaccine Response for Varicella Antibodies at Day 30 Post 12-Month Vaccination96.4 (94.7 to 97.7)94.7 (91.5 to 96.9)
SecondaryGroups 1a and 2a: GMCs of Anti-Pneumococcal Antibodies at Day 30 Post 12-Month Vaccination

GMCs of anti-pneumococcal antibodies was assessed by PnPS IgG ECL assay which is used to quantitate the amount of anti-streptococcus pneumoniae PS (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) antibodies in human serum.

Time frame:
Day 30 post 12-month vaccination (Month 13)
Reported as:
Geometric mean · mcg/mL
Groups 1a and 2a: GMCs of Anti-Pneumococcal Antibodies at Day 30 Post 12-Month Vaccination
mcg/mLGroup 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination)Group 2a: MENVEO (Post 12-month Vaccination)
Serotype 13.81 (3.56 to 4.08)3.44 (3.12 to 3.81)
Serotype 30.771 (0.728 to 0.817)0.751 (0.690 to 0.818)
Serotype 42.08 (1.95 to 2.22)2.00 (1.83 to 2.18)
Serotype 52.70 (2.53 to 2.88)2.46 (2.25 to 2.69)
Serotype 6A9.65 (9.09 to 10.2)9.51 (8.72 to 10.4)
Serotype 6B7.41 (6.92 to 7.93)6.37 (5.77 to 7.03)
Serotype 7F5.40 (5.08 to 5.73)6.04 (5.56 to 6.55)
Serotype 9V3.53 (3.31 to 3.77)3.62 (3.30 to 3.96)
Serotype 147.80 (7.26 to 8.38)9.20 (8.37 to 10.1)
Serotype 18C2.60 (2.44 to 2.78)2.92 (2.68 to 3.19)
Serotype 19A6.19 (5.82 to 6.59)5.86 (5.32 to 6.45)
Serotype 19F6.49 (6.11 to 6.90)6.01 (5.45 to 6.62)
Serotype 23F3.88 (3.60 to 4.17)3.41 (3.09 to 3.78)
SecondaryGroups 1b and 2b: Percentage of Participants Who Achieved Anti-PRP Antibody Concentrations >=1.0 mcg/mL at Day 30 Post 15-Month Vaccination

Anti-PRP concentrations were measured using a farr-type RIA. The percentage of participants with an PRP antibody titers \>=1.0 mcg/mL were assessed. Percentages are rounded off to the tenth decimal place.

Time frame:
Day 30 post 15-month vaccination (Month 16)
Reported as:
Number · percentage of participants
Groups 1b and 2b: Percentage of Participants Who Achieved Anti-PRP Antibody Concentrations >=1.0 mcg/mL at Day 30 Post 15-Month Vaccination
percentage of participantsGroup 1b:MenACYW Conjugate Vaccine(Post 15-month Vaccination)Group 2b: MENVEO (Post 15- Month Vaccination)
Groups 1b and 2b: Percentage of Participants Who Achieved Anti-PRP Antibody Concentrations >=1.0 mcg/mL at Day 30 Post 15-Month Vaccination98.3 (96.1 to 99.5)98.4 (94.3 to 99.8)
SecondaryGroups 1b and 2b: Percentage of Participants Who Achieved Anti-Poliovirus Antibody Titers >=1:8 at Day 30 Post 15-Month Vaccination

Anti-poliovirus types 1, 2, and 3 were measured by neutralization assay. The percentage of participants with anti-polio antibody titers \>=1:8 are assessed.

Time frame:
Day 30 post 15-month vaccination (Month 16)
Reported as:
Number · percentage of participants
Groups 1b and 2b: Percentage of Participants Who Achieved Anti-Poliovirus Antibody Titers >=1:8 at Day 30 Post 15-Month Vaccination
percentage of participantsGroup 1b:MenACYW Conjugate Vaccine(Post 15-month Vaccination)Group 2b: MENVEO (Post 15- Month Vaccination)
Anti-polio 1100 (98.7 to 100)100 (97.0 to 100)
Anti-polio 2100 (98.7 to 100)100 (97.0 to 100)
Anti-polio 3100 (98.7 to 100)100 (97.0 to 100)
SecondaryGroups 1b and 2b: Percentage of Participants Who Achieved Vaccine Response for Anti-Pertussis Antibodies at Day 30 Post 15-Month Vaccination

Vaccine response was defined as: if the pre-booster (4th) vaccination concentration was \<lower limit of quantification (LLOQ), then the post-booster (4th) vaccination concentration should be \>=4 times LLOQ. The LLOQ was equal to 2.00 EU/mL. Percentages are rounded off to the tenth decimal place.

Time frame:
Day 30 post 15-month vaccination (Month 16)
Reported as:
Number · percentage of participants
Groups 1b and 2b: Percentage of Participants Who Achieved Vaccine Response for Anti-Pertussis Antibodies at Day 30 Post 15-Month Vaccination
percentage of participantsGroup 1b:MenACYW Conjugate Vaccine(Post 15-month Vaccination)Group 2b: MENVEO (Post 15- Month Vaccination)
Anti-PT98.5 (96.3 to 99.6)98.3 (94.2 to 99.8)
Anti-FHA96.7 (93.8 to 98.5)96.7 (91.8 to 99.1)
Anti-PRN96.3 (93.4 to 98.2)97.5 (92.9 to 99.5)
Anti-FIM98.2 (95.8 to 99.4)97.5 (92.9 to 99.5)
SecondaryGroups 1a and 2a: Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA at Day 30 Post 6-Month Vaccination and Day 0 Before 12-Month Vaccination

GMTs of antibody against meningococcal serogroups A, C, Y, and W were measured by hSBA. PPAS2 included participants of FAS2 (subset of all randomized participants who received \>=1 dose of the study vaccine in infancy \[at Visit 1 to 3, \< 12 months of age\] and had a valid pre-vaccination serology result at Visit 5 before the 12-month vaccinations for Subgroups 1a and 2a or at Visit 6 before the 15-month vaccinations for Subgroups 1b and 2b) with no relevant protocol deviations during infancy and for whom a pre-dose serology sample at Visit 5 for Subgroups 1a and 2a before the 12-month vaccinations or Visit 6 for Subgroups 1b and 2b before the 15-month vaccinations was not withdrawn.

Time frame:
Day 30 post 6-month vaccination (Month 7) and Day 0 before 12-month vaccination (Month 12)
Reported as:
Geometric mean · titer
Groups 1a and 2a: Geometric Mean Titers (GMTs) of Antibodies Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA at Day 30 Post 6-Month Vaccination and Day 0 Before 12-Month Vaccination
titerGroup 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination)Group 2a: MENVEO (Post 12- Month Vaccination)
Serogroup A: Day 30 post 3rd dose24.9 (21.6 to 28.6)16.3 (13.5 to 19.6)
Serogroup A: Day 0 before 4th dose9.33 (8.45 to 10.3)6.43 (5.64 to 7.33)
Serogroup C: Day 30 post 3rd dose365 (325 to 411)51.4 (42.9 to 61.5)
Serogroup C: Day 0 before 4th dose57.8 (51.5 to 64.8)4.82 (4.22 to 5.50)
Serogroup Y: Day 30 post 3rd dose83.0 (75.0 to 91.8)42.9 (36.7 to 50.0)
Serogroup Y: Day 0 before 4th dose42.9 (39.3 to 46.7)10.4 (9.15 to 11.9)
Serogroup W: Day 30 post 3rd dose92.8 (84.8 to 102)51.4 (43.9 to 60.0)
Serogroup W: Day 0 before 4th dose57.8 (52.7 to 63.3)9.27 (8.15 to 10.5)
SecondaryGroups 1a and 2a: Percentage of Participants Who Achieved Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W at Day 30 Post 6-Month Vaccination and Day 0 Before 12-Month Vaccination

Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. PPAS2 included participants of FAS2 with no relevant protocol deviations during infancy and for whom a pre-dose serology sample at Visit 5 for Subgroups 1a and 2a before the 12-month vaccinations or Visit 6 for Subgroups 1b and 2b before the 15-month vaccinations was not withdrawn. Percentages are rounded off to the tenth decimal place.

Time frame:
Day 30 post 6-month vaccination (Month 7) and Day 0 before 12-month vaccination (Month 12)
Reported as:
Number · percentage of participants
Groups 1a and 2a: Percentage of Participants Who Achieved Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W at Day 30 Post 6-Month Vaccination and Day 0 Before 12-Month Vaccination
percentage of participantsGroup 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination)Group 2a: MENVEO (Post 12- Month Vaccination)
Serogroup A: D30 post 3rd dose:>=1:487.0 (83.9 to 89.7)84.9 (79.9 to 89.0)
Serogroup A: D30 post 3rd dose:>=1:877.3 (73.6 to 80.8)70.2 (64.2 to 75.7)
Serogroup A:D0 before 4th dose:>=1:482.5 (79.2 to 85.4)66.4 (60.9 to 71.5)
Serogroup A:D0 before 4th dose:>=1:859.0 (55.0 to 62.9)47.0 (41.5 to 52.7)
Serogroup C: D30 post 3rd dose:>=1:4 (n=)99.3 (98.1 to 99.8)93.7 (90.0 to 96.3)
Serogroup C: D30 post 3rd dose:>=1:899.1 (97.9 to 99.7)91.0 (87.0 to 94.2)
Serogroup C:D0 before 4th dose:>=1:495.4 (93.5 to 96.9)49.1 (43.5 to 54.7)
Serogroup C:D0 before 4th dose:>=1:892.9 (90.7 to 94.8)34.0 (28.8 to 39.4)
Serogroup Y: D30 post 3rd dose:>=1:499.1 (97.9 to 99.7)96.3 (93.3 to 98.2)
Serogroup Y: D30 post 3rd dose:>=1:898.6 (97.2 to 99.4)92.2 (88.4 to 95.1)
Serogroup Y:D0 before 4th dose:>=1:499.2 (98.2 to 99.7)83.5 (79.0 to 87.3)
Serogroup Y:D0 before 4th dose:>=1:896.8 (95.2 to 98.1)69.1 (63.8 to 74.1)
Serogroup W: D30 post 3rd dose:>=1:499.8 (99.0 to 100)97.5 (94.9 to 99.0)
Serogroup W: D30 post 3rd dose:>=1:898.8 (97.5 to 99.5)94.2 (90.8 to 96.7)
Serogroup W:D0 before 4th dose:>=1:498.9 (97.8 to 99.6)82.7 (78.1 to 86.6)
Serogroup W:D0 before 4th dose:>=1:897.2 (95.6 to 98.3)62.0 (56.5 to 67.3)

Adverse events

Collected over From first administration of study treatment (Day 0) up to 6-months post last administration of study treatment, approximately 24 months for Group 1 and 18 months for Group 2.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: MenACYW Conjugate Vaccine1/1,727 (0.1%)99/1,727 (5.7%)1,471/1,727 (85.2%)
Group 2: MENVEO0/867 (0%)38/867 (4.4%)746/867 (86%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO
BronchiolitisInfections and infestations15/17274/867
Respiratory Syncytial Virus InfectionInfections and infestations7/17276/867
Respiratory Syncytial Virus BronchiolitisInfections and infestations9/17274/867
Febrile ConvulsionNervous system disorders8/17273/867
DehydrationMetabolism and nutrition disorders3/17274/867
PneumoniaInfections and infestations6/17272/867
GastroenteritisInfections and infestations2/17273/867
Urinary Tract InfectionInfections and infestations2/17273/867
Respiratory DistressRespiratory, thoracic and mediastinal disorders4/17273/867
InfluenzaInfections and infestations4/17271/867
Most frequent other events
Showing 10 of 14
Most frequent other events
EventGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO
Injection Site PainGeneral disorders1201/1727637/867
IrritabilityPsychiatric disorders1154/1727598/867
CryingGeneral disorders1023/1727541/867
SomnolenceNervous system disorders975/1727507/867
Injection Site ErythemaGeneral disorders806/1727409/867
Decreased AppetiteMetabolism and nutrition disorders704/1727388/867
Injection Site SwellingGeneral disorders632/1727323/867
PyrexiaGeneral disorders580/1727312/867
VomitingGastrointestinal disorders417/1727196/867
Upper Respiratory Tract InfectionInfections and infestations214/1727130/867

Baseline characteristics

Baseline characteristics were assessed for all randomized participants.

Age, Continuous
Age, Continuous(days)Group 1: MenACYW Conjugate VaccineGroup 2: MENVEOTotal
Mean65.3 ± 8.0265.3 ± 7.8165.3 ± 7.95
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: MenACYW Conjugate VaccineGroup 2: MENVEOTotal
Female8284151243
Male9184661384
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: MenACYW Conjugate VaccineGroup 2: MENVEOTotal
American Indian or Alaska Native11314
Asian151025
Native Hawaiian or Other Pacific Islander7613
Black or African American20499303
White14287222150
More than one race443074
Unknown or Not Reported371148
08

Study locations

70 sites
  • Birmingham Pediatric Associates Site Number : 8400026
    Birmingham, Alabama 35205, United States
  • Southeastern Pediatric Associates Site Number : 8400003
    Dothan, Alabama 36305, United States
  • MedPharmics, LLC - Phoenix Site Number : 8400083
    Phoenix, Arizona 85015, United States
  • Northwest Arkansas Pediatric Clinic Site Number : 8400011
    Fayetteville, Arkansas 72703, United States
  • The Children's Clinic of Jonesboro, PA Site Number : 8400032
    Jonesboro, Arkansas 72401, United States
  • Emmaus Research Center, Inc Site Number : 8400031
    Anaheim, California 92804, United States
  • Premier Health Research Center Site Number : 8400007
    Downey, California 90241, United States
  • Joint Clinical Trials Huntington Park Site Number : 8400126
    Huntington Park, California 90255, United States
  • United Clinical Research Site Number : 8400092
    Huntington Park, California 90255, United States
  • Matrix Clinical Research Site Number : 8400095
    Los Angeles, California 90057, United States
  • Center for Clinical Trials, LLC Site Number : 8400030
    Paramount, California 90723, United States
  • Center for Clinical Trials of San Gabriel Site Number : 8400076
    West Covina, California 91790, United States
  • Asclepes Research Centers Site Number : 8400064
    Brooksville, Florida 34613, United States
  • Avail Clinical Research Site Number : 8400077
    DeLand, Florida 32720, United States
  • Next Phase Research Alliance Site Number : 8400057
    Hialeah, Florida 33013, United States
  • Homestead Medical Clinic, P.A. Site Number : 8400014
    Homestead, Florida 33030, United States
  • Next Phase Research Alliance Site Number : 8400040
    Homestead, Florida 33030, United States
  • Children's Research, LLC Site Number : 8400063
    Lake Mary, Florida 32746, United States
  • Axcess Medical Research Site Number : 8400068
    Loxahatchee Groves, Florida 33470, United States
  • Acevedo Clinical Research Associates Site Number : 8400001
    Miami, Florida 33186, United States
  • Florida Hospital Medical Group Pediatrics Site Number : 8400108
    Orlando, Florida 32803, United States
  • IMIC Inc Site Number : 8400022
    Palmetto Bay, Florida 33157, United States
  • Jedidiah Clinical Research Site Number : 8400132
    Tampa, Florida 33617, United States
  • Baybol Research Institute Site Number : 8400008
    Chamblee, Georgia 30341, United States
  • Snake River Research, PLLC Site Number : 8400073
    Idaho Falls, Idaho 83404, United States
  • Qualmedica Research, LLC Site Number : 8400106
    Evansville, Indiana 47715, United States
  • Brownsboro Park Pediatrics Site Number : 8400010
    Louisville, Kentucky 40207, United States
  • All Children Pediatrics Site Number : 8400043
    Louisville, Kentucky 40243, United States
  • ACC Pediatric Reasearch Site Number : 8400023
    Haughton, Louisiana 71037, United States
  • Velocity Clinical Research Site Number : 8400025
    Metairie, Louisiana 70006, United States
  • LSUHSC-Shreveport Site Number : 8400120
    Shreveport, Louisiana 71103, United States
  • University of Maryland at The Pediatric Center of Frederick Site Number : 8400004
    Frederick, Maryland 21702, United States
  • Virgo-Carter Pediatrics Site Number : 8400041
    Silver Spring, Maryland 20910, United States
  • MedPharmics Biloxi Site Number : 8400080
    Biloxi, Mississippi 39531, United States
  • Craig Spiegel, MD Site Number : 8400037
    Bridgeton, Missouri 63044, United States
  • Creighton University Site Number : 8400039
    Omaha, Nebraska 68131, United States
  • Tiga Pediatrics Site Number : 8400137
    New York, New York 10467, United States
  • Blue Pediatric & Adolescent Medicine Group Site Number : 8400100
    Boone, North Carolina 28607, United States
  • Ohio Pediatric Research Site Number : 8400084
    Dayton, Ohio 45414, United States
  • PriMed Clinical Research Site Number : 8400002
    Dayton, Ohio 454429, United States
  • Cyn3rgy Research Site Number : 8400085
    Gresham, Oregon 97030, United States
  • Allegheny Health and Wellness Pavilion Site Number : 8400047
    Erie, Pennsylvania 16505, United States
  • Coastal Pediatric Research Charleston Site Number : 8400005
    Charleston, South Carolina 29414, United States
  • Tribe Clinical Research Site Number : 8400110
    Greenville, South Carolina 29607, United States
  • Parkside Pediatrics - Simpsonville Site Number : 8400113
    Simpsonville, South Carolina 29681, United States
  • Pediatric Clinical Trials Tullahoma Site Number : 8400033
    Tullahoma, Tennessee 37388, United States
  • ARC Clinical Research at Wilson Parke Site Number : 8400059
    Austin, Texas 78726, United States
  • Oak Cliff Research Company, LLC Site Number : 8400065
    Dallas, Texas 75218, United States
  • Helios Clinical research Site Number : 8400075
    Fort Worth, Texas 76104, United States
  • University of North Texas Site Number : 8400079
    Fort Worth, Texas 76107-2699, United States
  • University of Texas Medical Board Site Number : 8400067
    Galveston, Texas 77555-0163, United States
  • Helios Clinical Research Site Number : 8400109
    Houston, Texas 77008, United States
  • Clinical Trial Network - 7080 Southwest Fwy Site Number : 8400114
    Houston, Texas 77074-2085, United States
  • FMC SCIENCE Site Number : 8400053
    Lampasas, Texas 76550, United States
  • Tekton Research, Inc Site Number : 8400049
    San Antonio, Texas 78229, United States
  • Tekton Research Site Number : 8400128
    San Antonio, Texas 78244, United States
  • Ericksen Research and Development Site Number : 8400016
    Clinton, Utah 84015, United States
  • Wee Care Pediatrics Site Number : 8400035
    Kaysville, Utah 84037, United States
  • Tanner Clinic Site Number : 8400018
    Layton, Utah 84041, United States
  • Pediatric Care Site Number : 8400056
    Provo, Utah 84064, United States
  • Wee Care Pediatrics Roy Site Number : 8400029
    Roy, Utah 84067, United States
  • Copperview Medical Center Site Number : 8400038
    South Jordan, Utah 84095, United States
  • Wee Care Pediatrics Syracuse Site Number : 8400024
    Syracuse, Utah 84075-9143, United States
  • Alliance for Multispecialty Research Syracuse Site Number : 8400036
    Syracuse, Utah 84075-9645, United States
  • Marshall Health Site Number : 8400062
    Huntington, West Virginia 25701, United States
  • Investigational Site Number : 6300116
    Caguas, 00726, Puerto Rico
  • Investigational Site Number : 6300122
    Guayama, 000784, Puerto Rico
  • Investigational Site Number : 6300015
    San Juan, 00918, Puerto Rico
  • Investigational Site Number : 6300117
    San Juan, 00918, Puerto Rico
  • Investigational Site Number : 6300140
    San Juan, 00935, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Sep 2023, 64 months.

Results were first posted in Oct 2024, 1 year after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 64 months is above that.

Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2018
First posted
May 25, 2018
StartActual
Apr 25, 2018
Primary completionActual
Sep 22, 2023
CompletionActual
Sep 22, 2023
Results first posted
Oct 15, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03537508
Responsible party
Sponsor
First posted
May 25, 2018
Start date
Apr 25, 2018
Primary completion
Sep 22, 2023
Completion
Sep 22, 2023
Results posted
Oct 15, 2024
Last update
Oct 15, 2024

Study contacts

Medical Director
study director · Sanofi Pasteur, a Sanofi Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion